Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.

PURPOSE Methotrexate (MTX) can cause significant clinical neurotoxicity and asymptomatic leukoencephalopathy. We sought to identify clinical, pharmacokinetic, and genetic risk factors for these MTX-related toxicities during childhood acute lymphoblastic leukemia (ALL) therapy and provide data on safety of intrathecal and high-dose MTX rechallenge in patients with neurotoxicity. PATIENTS AND METHODS Prospective brain magnetic resonance imaging was performed at four time points for 369 children with ALL treated in a contemporary study that included five courses of high-dose MTX and 13 to 25 doses of triple intrathecal therapy. Logistic regression modeling was used to evaluate clinical and pharmacokinetic factors, and a genome-wide association study (GWAS) was performed to identify germline polymorphisms for their association with neurotoxicities. RESULTS Fourteen patients (3.8%) developed MTX-related clinical neurotoxicity. Of 13 patients rechallenged with intrathecal and/or high-dose MTX, 12 did not experience recurrence of neurotoxicity. Leukoencephalopathy was found in 73 (20.6%) of 355 asymptomatic patients and in all symptomatic patients and persisted in 74% of asymptomatic and 58% of symptomatic patients at the end of therapy. A high 42-hour plasma MTX to leucovorin ratio (measure of MTX exposure) was associated with increased risk of leukoencephalopathy in multivariable analysis (P = .038). GWAS revealed polymorphisms in genes enriched for neurodevelopmental pathways with plausible mechanistic roles in neurotoxicity. CONCLUSION MTX-related clinical neurotoxicity is transient, and most patients can receive subsequent MTX without recurrence of acute or subacute symptoms. All symptomatic patients and one in five asymptomatic patients develop leukoencephalopathy that can persist until the end of therapy. Polymorphisms in genes related to neurogenesis may contribute to susceptibility to MTX-related neurotoxicity.

[1]  M. Relling,et al.  Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments , 2013, Cancer Chemotherapy and Pharmacology.

[2]  Cheng Cheng,et al.  Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Relling,et al.  Population PK/PD Model of Homocysteine Concentrations after High-Dose Methotrexate Treatment in Patients with Acute Lymphoblastic Leukemia , 2012, PloS one.

[4]  C. Pui,et al.  Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. , 2012, Journal of the National Cancer Institute.

[5]  Thomas Meitinger,et al.  Genome-wide association analysis identifies susceptibility loci for migraine without aura , 2012, Nature Genetics.

[6]  D. Cheon,et al.  Echovirus 30 Induced Neuronal Cell Death through TRIO-RhoA Signaling Activation , 2012, PloS one.

[7]  John Wei,et al.  Identify Risk Genes for ADHD Rare Copy Number Variation Discovery and Cross-Disorder Comparisons , 2011 .

[8]  M. Salminen,et al.  Netrin1 is required for neural and glial precursor migrations into the olfactory bulb. , 2011, Developmental biology.

[9]  Jaak Vilo,et al.  g:Profiler—a web server for functional interpretation of gene lists (2011 update) , 2011, Nucleic Acids Res..

[10]  S. Raimondi,et al.  Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Gervasini,et al.  Methotrexate‐induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis , 2011, American journal of hematology.

[12]  W. Reddick,et al.  Impact of acute lymphoblastic leukemia therapy on attention and working memory in children , 2010, Expert review of hematology.

[13]  M. Hatten,et al.  Astn2, A Novel Member of the Astrotactin Gene Family, Regulates the Trafficking of ASTN1 during Glial-Guided Neuronal Migration , 2010, The Journal of Neuroscience.

[14]  S. Bassett,et al.  Fine mapping of the chromosome 10q11-q21 linkage region in Alzheimer's disease cases and controls , 2010, neurogenetics.

[15]  Cheng Cheng,et al.  Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Cheng Cheng,et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.

[17]  Robert T. Schultz,et al.  Autism genome-wide copy number variation reveals ubiquitin and neuronal genes , 2009, Nature.

[18]  F. Hofmann,et al.  Regulate Axon Branching by the Cyclic GMP Pathway via Inhibition of Glycogen Synthase Kinase 3 in Dorsal Root Ganglion Sensory Neurons , 2009, The Journal of Neuroscience.

[19]  U. Jaehde,et al.  Methotrexate‐associated alterations of the folate and methyl‐transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity , 2009, Pediatric blood & cancer.

[20]  M. Rasband,et al.  Spectrin and Ankyrin-Based Cytoskeletons at Polarized Domains in Myelinated Axons , 2008, Experimental biology and medicine.

[21]  Matthew A. Zapala,et al.  Gene expression in mouse brain following chronic hypoxia: role of sarcospan in glial cell death. , 2008, Physiological genomics.

[22]  Christian Urban,et al.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. , 2007, Blood.

[23]  E. Cook,et al.  Ancestry and pharmacogenetics of antileukemic drug toxicity. , 2007, Blood.

[24]  A. Baruchel,et al.  Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children , 2007, Leukemia.

[25]  A. Veerman,et al.  Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor , 2006, Cancer.

[26]  C. Pui,et al.  A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. , 2005, AJNR. American journal of neuroradiology.

[27]  C. Pui,et al.  Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. , 2005, AJNR. American journal of neuroradiology.

[28]  Stefan Krauss,et al.  Characterisation of the Wnt antagonists and their response to conditionally activated Wnt signalling in the developing mouse forebrain. , 2004, Brain research. Developmental brain research.

[29]  N. Winick,et al.  Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. , 2004, AJNR. American journal of neuroradiology.

[30]  Winnie C W Chu,et al.  White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: longitudinal study with MR imaging and 1H MR spectroscopy. , 2003, Radiology.

[31]  E. Cook,et al.  Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Oka,et al.  MRI in methotrexate-related leukoencephalopathy: Disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy , 2003, Neuroradiology.

[33]  U. Jaehde,et al.  Biochemical and Clinical Aspects of Methotrexate Neurotoxicity , 2003, Chemotherapy.

[34]  D. V. Vactor,et al.  The Trio family of guanine-nucleotide-exchange factors: regulators of axon guidance. , 2001, Journal of cell science.

[35]  E. Pääkkö,et al.  White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: correlation with neuropsychological findings. , 2000, Medical and pediatric oncology.

[36]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[37]  C. Pui,et al.  Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia , 1998, Leukemia.

[38]  N. Winick,et al.  Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Fort,et al.  Aminophylline for methotrexate-induced neurotoxicity , 1995, The Lancet.

[40]  Yukio Miki,et al.  Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate , 1992, Cancer.

[41]  N. Winick,et al.  Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. , 1992, Journal of the National Cancer Institute.

[42]  O. Dulac,et al.  Necrotising leukoencephalopathy complicating treatment of childhood leukaemia. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[43]  M. Relling,et al.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. , 2010, Blood.

[44]  M. Daly,et al.  Case-control genome-wide association study of attention-deficit/hyperactivity disorder. , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.

[45]  V. Vijayanathan,et al.  Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. , 2009, Pediatric neurology.

[46]  C. Pui,et al.  Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  J. Friedman,et al.  Classification and Regression Trees , 1984 .

[48]  H. Gierowska.  [For children...]. , 1971, Pielegniarka i polozna.